goserelin,tamoxifen
not tagged
['bcsm']
astrra: 5y tamoxifen +/- 2y goserelin in women who remained premenopausal after surgery and chemo. median age 40. 55% n+. 8y dfs benefit 5.2%. os benefit not statistically significant. hee jeong kim of #asco22 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.